Literature DB >> 14553853

Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery.

Anees Chagpar1, Tina Yen, Aysegul Sahin, Kelly K Hunt, Gary J Whitman, Frederick C Ames, Merrick I Ross, Funda Meric-Bernstam, Gildy V Babiera, S Eva Singletary, Henry M Kuerer.   

Abstract

BACKGROUND: Reported rates of reexcision for margin control after breast-conserving surgery for ductal carcinoma in situ (DCIS) range from 48% to 59%. The optimal technique for intraoperative margin assessment in patients with DCIS has yet to be defined. We sought to determine whether intraoperative multidisciplinary evaluation using gross tissue assessment and sectioned-specimen radiography reduces the need for reoperation for margin control in DCIS.
METHODS: A prospectively compiled database was used to identify patients who had DCIS diagnosed by core needle biopsy and were treated with breast-conserving surgery at our institution between July 1999 and July 2002. All patients had intraoperative gross margin assessment and specimen radiography of both the whole and sliced specimen for calcifications.
RESULTS: Four hundred two patients with DCIS were evaluated at our institution during the study period. Of these, 160 had excisional biopsy for diagnosis prior to referral, 92 had mastectomy as their initial procedure, 40 were seen for a second opinion only, and 1 patient refused surgery. The remaining 109 patients formed the study population. The median age was 55 years (range 34 to 81). The median pathologic size of DCIS was 1.2 cm (range 0.2 to 8.0 cm). Fifty-nine patients had positive (less than 1 mm) or close (less than 5 mm) margins on intraoperative assessment. Final pathology agreed with intraoperative assessment of a positive or close margin in 43 of the 59 patients (P = 0.00005). Seventy-five percent of those thought to have a positive or close margin at the time of surgery (n = 44) underwent intraoperative reexcision. Of the total 109 patients, 31 (34%) had an intraoperative reexcision that resulted in a change in margin status from positive on intraoperative evaluation to negative on final pathologic evaluation (P < 0.00001). A second procedure for margin control was necessary in only 24 patients (22%). The decision to excise additional tissue at the first surgery on the basis of intraoperative assessment resulted in significantly fewer second procedures for margin control (P = 0.029).
CONCLUSIONS: In patients with DCIS, intraoperative margin assessment by gross pathological examination and sliced specimen radiography significantly affects intraoperative decision making, and excision of further tissue on the basis of intraoperative assessment results in a substantial decrease in second procedures for margin control.

Entities:  

Mesh:

Year:  2003        PMID: 14553853     DOI: 10.1016/s0002-9610(03)00264-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  32 in total

1.  Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions.

Authors:  Jason P Holland; Guillaume Normand; Alessandro Ruggiero; Jason S Lewis; Jan Grimm
Journal:  Mol Imaging       Date:  2011-06       Impact factor: 4.488

Review 2.  Recent developments in breast-conserving surgery for breast cancer patients.

Authors:  F Fitzal; O Riedl; R Jakesz
Journal:  Langenbecks Arch Surg       Date:  2008-09-10       Impact factor: 3.445

3.  Flexible silicon sensors for diffuse reflectance spectroscopy of tissue.

Authors:  David M Miller; Nan M Jokerst
Journal:  Biomed Opt Express       Date:  2017-02-14       Impact factor: 3.732

4.  Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins.

Authors:  S E Tevis; H B Neuman; E A Mittendorf; H M Kuerer; I Bedrosian; S M DeSnyder; A M Thompson; D M Black; M E Scoggins; A A Sahin; K K Hunt; A S Caudle
Journal:  Ann Surg Oncol       Date:  2018-06-26       Impact factor: 5.344

5.  Efficacy of intraoperative entire-circumferential frozen section analysis of lumpectomy margins during breast-conserving surgery for breast cancer.

Authors:  Tomofumi Osako; Reiki Nishimura; Yasuyuki Nishiyama; Yasuhiro Okumura; Rumiko Tashima; Masahiro Nakano; Mamiko Fujisue; Yasuo Toyozumi; Nobuyuki Arima
Journal:  Int J Clin Oncol       Date:  2015-04-09       Impact factor: 3.402

6.  Intraoperative Pathologic Margin Analysis and Re-Excision to Minimize Reoperation for Patients Undergoing Breast-Conserving Surgery.

Authors:  Jennifer M Racz; Amy E Glasgow; Gary L Keeney; Amy C Degnim; Tina J Hieken; James W Jakub; John C Cheville; Elizabeth B Habermann; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2020-07-04       Impact factor: 5.344

7.  The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer.

Authors:  Xiaoxian Li; Michael T Deavers; Ming Guo; Ping Liu; Yun Gong; Constance T Albarracin; Lavinia P Middleton; Lei Huo
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

8.  Use of MRI in preoperative planning for women with newly diagnosed DCIS: risk or benefit?

Authors:  Kathryn L Davis; Richard J Barth; Jiang Gui; Elizabeth Dann; Burton Eisenberg; Kari Rosenkranz
Journal:  Ann Surg Oncol       Date:  2012-08-22       Impact factor: 5.344

9.  The Role of Intraoperative Pathologic Assessment in the Surgical Management of Ductal Carcinoma In Situ.

Authors:  Marquita R Decker; Amy Trentham-Dietz; Noelle K Loconte; Heather B Neuman; Maureen A Smith; Rinaa S Punglia; Caprice C Greenberg; Lee G Wilke
Journal:  Ann Surg Oncol       Date:  2016-03-29       Impact factor: 5.344

10.  High and intermediate grade ductal carcinoma in-situ of the breast: a comparison of pathologic features in core biopsies and excisions and an evaluation of core biopsy features that may predict a close or positive margin in the excision.

Authors:  Oluwole Fadare; Nathan F Clement; Mohiedean Ghofrani
Journal:  Diagn Pathol       Date:  2009-08-19       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.